Dr Jeff Sharman speaks to ecancer at the 2019 ASH meeting in Orlando about the latest results from the phase III ELEVATE TN trial.
He describes the background of the trial, which aims to assess the efficacy and safety of acalabrutinib plus obinutuzumab versus acalabrutinib alone or obinutuzumab plus chlorambucil in patients with treatment-naïve chronic lymphocytic leukaemia (CLL).
Dr Sharman reports the main results from this phase of the trial, which found that acalabrutinib monotherapy and in combination with obinutuzumab significantly improved progression-free survival, compared to the control arm of obinutuzumab plus chlorambucil.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.